Effectiveness of an artificial intelligence-based self-management intervention to support sick-listed individuals with musculoskeletal disorders in Norway: rationale and protocol for the SmaRTWork randomised controlled trial.

Authors

Lene Aasdahl, Kerstin Bach, Tom Ivar Lund Nilsen, Stuart Gallina Ottersen, Nina E Klevanger, Christoph Eder, Cecilie Krage Øverås, Fredrik Granviken, Julia Debik, Lars Christian Naterstad Lervik, Heidi Fossen, Anita Formo Bones, Sigmund Gismervik, Karen W Hara, Paul Jarle Mork

Published in

BMJ open. Volume 16. Issue 8. Pages e122680. Aug 18, 2026. Epub Aug 18, 2026.

Abstract

Long-term sickness absence represents a major public health challenge with far-reaching consequences for both individuals and society. Musculoskeletal disorders (MSDs) are among the leading causes of sickness absence. Although mobile apps show promise for supporting self-management of MSDs, high-quality evidence remains limited, and outcomes related to work participation are rarely examined. This trial aims to evaluate whether an individually tailored, app-based self-management intervention (SmaRTWork), provided in addition to usual care, improves return-to-work compared with usual care alone among individuals on sick leave due to MSDs.
We will conduct a randomised controlled trial with two parallel arms: 1) SmaRTWork in addition to usual care and 2) usual care alone. Individuals 20-59 years old who have been sick-listed for <12 weeks due to back, neck or widespread pain will be recruited through clinicians in primary health care. Eligible participants are randomised 1:1 to one of the two arms. We aim to include 298 participants, 149 in each arm. The primary outcome is time to sustainable return-to-work, defined as one consecutive month without receiving medical benefits, assessed over a 12-month period using registry data. Secondary outcomes include health-related measures assessed at baseline, 3, 6 and 12 months. The trial will also incorporate qualitative studies, a process evaluation and a health economic evaluation.
The trial is approved by the Committees for Clinical Trials of Pharmaceuticals and Medical Devices (Ref. 563919). Results will be published in peer-reviewed journals and presented at national and international conferences.
NCT07034040.

PMID:
42613108
Bibliographic data and abstract were imported from PubMed on 19 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.